Exploiter l’IA pour l’évaluation stratégique du marché après la perte d’exclusivité (LOE) en 2025
Client
A leading pharmaceutical company specializing in anti-infective treatments, with a key product facing loss of exclusivity (LOE) in 2025. The client operates in the hospital and retail sectors and is seeking advanced, data-driven strategies to maintain market share and profitability post-loss of exclusivity.
Objectif principal
Conduct comprehensive market analysis after PE to assess competitors, price changes, and buyer behavior, leveraging AI insights for analog selection, strategic positioning, and resource optimization to protect market share, maintain price integrity, and improve decision-making efficiency.
Capacité de Vamstar
Perspectives améliorées
Optimisation des prix avec l’IA
Analyse concurrentielle
Protection des marges
Facing the loss of exclusivity (PE) in 2025 for an anti-infective product, a leading pharmaceutical company needs solid insights into post-PE market dynamics. The product, a critical treatment sold in the hospital and retail sectors, has faced competitive pressures and high pricing.
Vamstar used its proprietary AI to analyze market trends, competitor strategies, and buyer behaviors. This involved leveraging vast datasets and AI algorithms to provide actionable strategic options and effectively defend market share.
The client expected precise, data-driven recommendations to mitigate risks, optimize resource allocation and refine competitive strategies, ensuring sustainable profitability and market presence.
Principaux résultats
Analyse approfondie du marché après la perte d’exclusivité
Optimisation basée sur l’intelligence artificielle : précision dans la modélisation des prix et des stratégies
Étude des concurrents, détermination des principales menaces et opportunités
Efficacité des ressources: Répartition des efforts commerciaux en fonction des données
Marges soutenues: Minimisation de l’érosion par la tarification stratégique
Parcours de transformation
- Avant Vamstar
- Pendant l’engagement de Vamstar
- Après Vamstar
The pharmaceutical company faced a legacy approach to market assessment that relied heavily on traditional consulting firms. These firms provided narrow, human-only analyses that lacked scalability, accuracy, and data depth. Market intelligence was fragmented, with analogous selection processes based on subjective judgment rather than comprehensive data.
This approach led to significant inefficiencies: analog selection was slow, critical competitive signals were missed, and often did not match real market dynamics. Intelligence was reactive, providing limited strategic value and leaving the company vulnerable to competitive pressures and rapid price erosion.
The lack of predictive analytics and forward-looking strategies created a strategic blind spot, preventing the company from effectively addressing post-LOE challenges and maintaining its market position.
Exploiter l’IA pour stimuler la croissance
Faites un pas vers l’amélioration de vos opérations commerciales, inscrivez-vous dès aujourd’hui
